Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2000-02-08
2001-07-24
Fredman, Jeffrey (Department: 1655)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C435S091200, C514S04400A, C536S023100, C536S024300
Reexamination Certificate
active
06265172
ABSTRACT:
TECHNICAL FILED OF THE INVENTION
The present invention relates to a diagnostic test and diagnostic kit for disease associated with decreased superoxide dismutase transcriptional activity. The present invention also relates to method of treating such diseases by augmentation of superoxide dismutase levels in affected tissues and cells.
BACKGROUND OF THE INVENTION
Aerobic organisms possess antioxidant defense systems that modulate reactive oxygen species (ROS). The superoxide dismutase (SODs) catalyze the dismutation of superoxide radicals into hydrogen peroxide and molecular oxygen. Hydrogen peroxide is further detoxified by catalase and glutathione peroxidase (Halliwell and Gutterbridge, 1989). Three distinct SODs are found in human cells; a monodimeric cytosolic CuZnSOD (McCord and Fridovich, 1969); an extracellular homotetrameric glycosylated CuZnSOD (ECSOD) (Marklund, 1982); and a mitochondrial matrix homotetrameric MnSOD (Weisiger and Fridovich, 1973).
Accumulating data suggest that MnSOD constitutes one of the major cellular defense mechanism against the toxic effects of agents that cause oxidative stress. It has been demonstrated that MnSOD knockout mice develop cardiomyopathy and neonatal lethality, whereas independent disruption of the genes for CuZnSOD and ECSOD isoenzymes result in viable, normal mice under nonstress conditions (reviewed in Yen and St. Clair, 1997). Furthermore, transgenic mice expressing human MnSOD in the mitochondria are protected from oxygen-induced cardiac injury (Yen et al., 1996), and ischemia-induced brain injury (Keller et al., 1998).
Numerous studies using gene transfection have demonstrated that transfection of MnSOD into tumor cells reverse the malignant phenotypes of tumor cells, suggesting that MnSOD functions to suppress tumorigenicity (reviewed in St. Clair et al., 1997). Transfection of human MnSOD cDNA into mouse fibroblasts prevents radiation-induced neoplastic transformation (St. Clair et al. 1992). Expression of the human MnSOD gene in mouse C3H10T1/2 cells enhances cellular differentiation upon treatment with 5-azacytidine (St. Clair et al. 1994). The malignant phenotype of human melanoma cells was suppressed by introduction of human chromosome
6
where the MnSOD gene is located (Trent et al. 1990) or transfection of a human MnSOD cDNA (Church et al., 1993). Overexpression of MnSOD suppressed the malignant phenotypes of human breast cancer cells (Li et al. 1995), human glioma cells (Zhong et al., 1997), and mouse epidermal cells (Amstad et al., 1997). The number of cells required to produce tumors in syngenic mice was markedly increased for the MnSOD-transfected murine fibrosarcoma cells lines (MnSOD-Fsa-II) compared to the vector-transfected control cells (St. Clair et al., 1997). The frequency of metastases was reduced in syngenic mice carrying the MnSOD transfected-FsaII cells compared to the mice bearing the control FsaII cells (Stafford et al., 1994). Furthermore the radiation dose required to control one-half of the irradiate tumor (TCD50) was greatly reduced when the MnSOD-FsaII cells were transplanted and irradiated in vivo under hypoxic conditions (Urano et al., 1995). Taken together, the evidence from these studies supports a hypothesis proposed by Oberley and Oberley (1984) that MnSOD plays an important role in the prevention of cancer development.
It has been shown that many types of human cancer cells have reduced MnSOD activity compared to their appropriate normal counterpart cells; (oberley and Buettner, 1979). The reduced level of MnSOD activity in human cancer cells is not due to a defect in the primary structure of the MnSOD protein, a change in the dosage of the MnSOD gene, or a decrease in the stability of MnSOD mRNA in tumor cells, but rather is due to defects in the expression of the gene (St. Clair and Holland, 1991).
The present inventors previously cloned and sequenced the entire human MnSOD gene, including a 0.7 kb 5′ flanking region, from a genomic library obtained from normal human lung fibroblast cells. The gene is characterized by the lack of TATA or CAAT box regulatory elements and the presence of a GC-rich region containing multiple SP-1 binding sites (Wan et al., 1994).
Prior research has failed to elucidate the cause for reduced expression of MnSOD in tumor cells. The present inventors have undertaken extensive research in order to solve this problem, and have accomplished this result by discovering several highly conserved mutations in the promoter region of the MnSOD gene.
In order to elucidate the cause for the reduced expression of human MnSOD in tumor cells, the present inventors have now further sequenced the 5′ flanking region of the human SOD gene and compared that to the 5′ flanking region of the human MnSOD gene from several tumor cell lines. The results demonstrate three heterozygous mutations n the promoter region of the human MnSOD gene in 5 of 14 tumor cell lines examined. Significantly these mutations were conserved amongst 3 of 5 colon cancer cell lines studied. The effect of these mutations on the transcription activity of the human MnSOD promoter was also determined by means of a reporter gene constructs. These results demonstrated markedly reduced gene expression when compared to transcriptional activation of the normal, wild-type MnSOD promoter.
An object of the present invention is to provide a diagnostic kit and a diagnostic method for assaying the presence of superoxide dismutase gene mutations associated with decreased enzyme activity seen in many diseases. Specifically, this invention aims at providing a diagnostic kit and method for certain cancers associated with reduced MnSOD expression. Another object of the present invention is to provide a diagnostic test and a diagnostic kit for Amylotrophic Lateral Sclerosis, ALS, which his also associated with reduced MnSOD activity.
Another objection of the present invention is to provide a therapeutic method targeted at disease associated with decreased MnSOD activity, and more specifically targeted at cancer and ALS.
SUMMARY OF THE INVENTION
It is one of the principal objectives of the present invention to provide a diagnostic kit and a diagnostic test for the detection of MnSOD mutations associated with various diseases. It is a further object to provide such a diagnostic kit and method for cancer. The present invention provides an assay which detects mutations in the regulatory region of MnSOD gene by a variety of methods comprising RFLP analysis, in conjunction with PCR amplification or DNA hybridization (Southern Blotting) utilizing a labeled oligonucleotide probe complementary to the MnSOD promoter/enhancer.
The present invention also provides a therapeutic method directed to MnSOD associated diseases which comprises augmentation of MnSOD activity by transfection of affected cells or tissues with high activity MnSOD expression vectors, or administration of exogenous MnSOD enzyme of these sites.
REFERENCES:
patent: 5436162 (1995-07-01), Heckl et al.
patent: 5604099 (1997-02-01), Erlich et al.
patent: 5900358 (1999-05-01), Ludwig et al.
Stratagene Catalog, p. 39, 1988.*
St. Clair et al, “Complementary DNA encoding human colon cancer manganese superoxide dismutase and the expression of its gene in human cells”, Cancer Research 51:939-943, Feb. 1991.*
Miele et al, “SOD2 (MnSOD) does not suppress tumorigenicity or metastasis of human melanoma C8161 cells”, Anticancer Res. 15:2065-2070, 1995.*
Tomblyn et al, “Distribution of MnSOD polymorphisms in sporadic ALS patients”, J. Mol. Neuroscience 10:65-66, 1998.*
Fernandez-Trigo, Am J. Clin. Oncol. 18(5):454-60 Abstract Only, 1995.*
Harris et al, “Strategies for targeted gene therapy”, Trends Genetics 12(10):400-405, 1996.*
Marshall, “Gene therapy's growing pains”, Science 269:1050-55, 1995.*
Xu et al, “Mutations in the promoter reveal a cause for the reduced expression of human manganese superoxide dismutase gene in cancer cells” Oncogene 18:93-102, Jan. 1999.
Kasarskis Edward J.
St. Clair Daret K.
Urano Muneyasu
Fredman Jeffrey
McDermott & Will & Emery
University of Kentucky
LandOfFree
Diagnostic test and therapy for manganese superoxide... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Diagnostic test and therapy for manganese superoxide..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Diagnostic test and therapy for manganese superoxide... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2528669